Robert Redfield serves as Executive at Traws Pharma, Inc., where they oversee executive responsibilities. Since joining the company, Robert Redfield has executed 2 insider transactions totaling $0, demonstrating a balanced approach to their equity position. Their most recent transaction on Dec 12, 2025 involved receiving (via award) 16,419 shares valued at $0.
Robert Redfield currently holds 113,919 shares of Traws Pharma, Inc. (TRAW), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Robert Redfield has been a net neutral trader of TRAW stock. They have purchased $0 and sold $0 worth of shares.
Robert Redfield's most recent insider trade was on Dec 12, 2025, when they sold 16,419 shares at $0.00 per share.
Get notified when new Form 4 filings are submitted
| $N/A |
| Discretionary |